Table 1 Patient demographics and baseline characteristics in reversible and non-reversible patients at screening
Characteristic | ITT (N = 2425) | Reversible (N = 625) | Non-reversible (N = 1799) |
|---|---|---|---|
Age, years, mean (SD) | 64.6 (8.5) | 63.5 (8.4) | 65.0 (8.5) |
Female, n (%) | 988 (41) | 200 (32) | 788 (44) |
No maintenance medication during run-in, n (%) | 749 (31) | 250 (40) | 499 (28) |
Moderate COPD exacerbation in prior yeara, n (%) | 393 (16) | 84 (13) | 309 (17) |
Duration of COPD, years, mean (SD) | 8.3 (6.6) | 8.4 (6.0) | 8.3 (6.8) |
Post-salbutamol FEV1, mL, mean (SD) | 1595 (511) | 1455 (478) | 1502 (529) |
Post-salbutamol % predicted FEV1, mean (SD) | 55.4 (12.7) | 56.0 (12.0) | 55.3 (13.0) |
Rescue salbutamol, puffs/day, mean (SD) | 2.2 (2.5) | 2.7 (2.9) | 2.0 (2.3) |
GOLD spirometric gradeb, n (%) | |||
2 | 1569 (65) | 416 (67) | 1153 (64) |
3 | 851 (35) | 207 (33) | 644 (36) |
% reversibility to salbutamol, mean (SD) | 10.5 (13.1) | 26.2 (13.3) | 5.0 (7.4) |
CAT score, mean (SD) | 19.2 (6.0) | 20.0 (6.5) | 18.9 (6.0) |
BDI score, mean (SD) | 7.0 (1.9) | 7.0 (2.0) | 7.0 (1.8) |
E-RS total score | 10.6 (5.7) | 11.7 (5.9) | 10.2 (5.6) |
SGRQ score, mean (SD) | 44.7 (16.2) | 46.3 (17.3) | 44.1 (15.7) |